Journal article

Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort

Jennifer Ose, Helena Schock, Anne Tjonneland, Louise Hansen, Kim Overvad, Laure Dossus, Francoise Clavel-Chapelon, Laura Baglietto, Heiner Boeing, Antonia Trichopolou, Vassiliki Benetou, Pagona Lagiou, Giovanna Masala, Giovanna Tagliabue, Rosario Tumino, Carlotta Sacerdote, Amalia Mattiello, HB As Bueno-de-Mesquita, Petra HM Peeters, N Charlotte Onland-Moret Show all

Cancer Epidemiology Biomarkers & Prevention | AMER ASSOC CANCER RESEARCH | Published : 2015

Abstract

BACKGROUND: Evidence suggests an etiologic role for inflammation in ovarian carcinogenesis and heterogeneity between tumor subtypes and anthropometric indices. Prospective studies on circulating inflammatory markers and epithelial invasive ovarian cancer (EOC) have predominantly investigated overall risk; data characterizing risk by tumor characteristics (histology, grade, stage, dualistic model of ovarian carcinogenesis) and anthropometric indices are sparse. METHODS: We conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort to evaluate C-reactive protein (CRP), IL6, and EOC risk by tumor characteristics. A total of 754 eligib..

View full abstract

Grants

Awarded by ERC-AdG (Norway)


Awarded by Regional Government of Murcia (Spain)


Awarded by ISCIII RETIC (Spain)


Awarded by Cancer Research UK (United Kingdom)


Awarded by Medical Research Council (United Kingdom)


Awarded by Cancer Research UK


Awarded by Medical Research Council


Awarded by National Institute for Health Research


Funding Acknowledgements

The German Cancer Research Center, Division of Cancer Epidemiology (Principal Investigator: Rudolf Kaaks) funded the analysis for this study. The coordination of the European Prospective Investigation into Cancer and Nutrition is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM; France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); Hellenic Health Foundation (Greece) and the Stavros Niarchos Foundation; Italian Association for Research on Cancer (AIRC) and National Research Council (Italy); Dutch Ministry of Public Health, Welfare, and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition, and Health (Norway); Health Research Fund (FIS), Regional Governments of Andalucia, Asturias, Basque Country, Murcia (no. 6236) and Navarra, ISCIII RETIC (RD06/0020; Spain); Swedish Cancer Society, Swedish Scientific Council, and Regional Government of Skane and Vasterbotten (Sweden); Cancer Research UK [no. 14136 (to K.-T. Khaw), no. C570/A16491 (to R.C. Travis)], Medical Research Council (United Kingdom; no. G1000143).